213 related articles for article (PubMed ID: 24778401)
1. Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma.
Johnson DB; Saranga-Perry V; Lavin PJ; Burnette WB; Clark SW; Uskavitch DR; Wallace DE; Dickson MA; Kudchadkar RR; Sosman JA
J Clin Oncol; 2015 Nov; 33(33):e122-4. PubMed ID: 24778401
[No Abstract] [Full Text] [Related]
2. Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma.
Kyllo RL; Parker MK; Rosman I; Musiek AC
J Am Acad Dermatol; 2014 Apr; 70(4):e85-e86. PubMed ID: 24629370
[No Abstract] [Full Text] [Related]
3. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H
Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab approved for metastatic melanoma.
Traynor K
Am J Health Syst Pharm; 2011 May; 68(9):768. PubMed ID: 21515855
[No Abstract] [Full Text] [Related]
5. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.
Liao B; Shroff S; Kamiya-Matsuoka C; Tummala S
Neuro Oncol; 2014 Apr; 16(4):589-93. PubMed ID: 24482447
[TBL] [Abstract][Full Text] [Related]
6. Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.
Emile J; Cauquil C; Carpentier D; Routier E; Robert C
Eur J Cancer; 2024 Jul; 205():114098. PubMed ID: 38761774
[No Abstract] [Full Text] [Related]
7. Vedolizumab: a novel treatment for ipilimumab-induced colitis.
Hsieh AH; Ferman M; Brown MP; Andrews JM
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27539137
[TBL] [Abstract][Full Text] [Related]
8. Systematic review: surgery for patients with metastatic melanoma during active treatment with ipilimumab.
Baker JJ; Stitzenberg KB; Collichio FA; Meyers MO; Ollila DW
Am Surg; 2014 Aug; 80(8):805-10. PubMed ID: 25105403
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
11. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP; Woodman SE
Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
[TBL] [Abstract][Full Text] [Related]
12. Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma.
Koch C; Paetzold S; Trojan J
Gastroenterology; 2012 Aug; 143(2):298, 504, 505. PubMed ID: 22709738
[No Abstract] [Full Text] [Related]
13. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
[No Abstract] [Full Text] [Related]
14. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
Eggermont AMM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbe C; Ferraresi V; Smylie M; Weber JS; Maio M; Hosein F; de Pril V; Kicinski M; Suciu S; Testori A
Eur J Cancer; 2019 Sep; 119():1-10. PubMed ID: 31400634
[TBL] [Abstract][Full Text] [Related]
15. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
16. NICE guidance on ipilimumab for treating previously untreated advanced (unresectable or metastatic) melanoma.
Hall CJ; Doss S; Robertson J; Adam J
Lancet Oncol; 2014 Sep; 15(10):1056-7. PubMed ID: 25328937
[No Abstract] [Full Text] [Related]
17. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bastholt L; Mortier L; Thomas L; Tahir S; Hauschild A; Hassel JC; Hodi FS; Taitt C; de Pril V; de Schaetzen G; Suciu S; Testori A
N Engl J Med; 2016 Nov; 375(19):1845-1855. PubMed ID: 27717298
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab-associated ocular myasthenia gravis.
Liu Q; Ayyappan S; Broad A; Narita A
Clin Exp Ophthalmol; 2019 Aug; 47(6):796-798. PubMed ID: 30859689
[No Abstract] [Full Text] [Related]
19. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
20. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
Ascierto PA
Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
